{"id":"W4399993529","doi":"10.1016/s1470-2045(24)00211-0","title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; University of Saskatchewan","funders":"National Cancer Institute; EMD Serono; Ipsen; Eisai; National Institutes of Health; ECOG-ACRIN Cancer Research Group; Canadian Cancer Society; Sanofi; Exelixis; Dana-Farber/Harvard Cancer Center; Genentech; Coherus Biosciences; Bristol-Myers Squibb; Pfizer; Dana-Farber Cancer Institute; American College of Radiology Imaging Network; Veracyte","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Nephrectomy; Clinical endpoint; Perioperative; Kidney cancer; Internal medicine; Surgery; Clinical trial; Urology; Cancer; Kidney; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001593731,0.001394858,0.002930129,0.0002270477,0.0003477164,0.001058952,0.0006847287,0.001152081,0.003432487],"category_scores_gemma":[0.00176138,0.0004990408,0.00333138,0.0002857826,0.001009442,0.001191743,0.0004403699,0.00323111,0.000620613],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008222826,"about_ca_system_score_gemma":0.0009431964,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001195338,"about_ca_topic_score_gemma":0.003514112,"domain_scores_codex":[0.9992903,0.0004377931,0.00003752806,0.00009582871,0.00004157414,0.00009690127],"domain_scores_gemma":[0.9992742,0.0002479984,0.0001855655,0.00006560052,0.00004223283,0.0001843613],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9746439,0.001932429,0.0007372561,0.001100836,0.002007455,0.00002175963,0.00004859409,0.0004505744,0.001100642,0.0001022488,0.0005926421,0.0172617],"study_design_scores_gemma":[0.912865,0.07873135,0.004288068,0.0001411648,0.001678525,0.00004029183,0.00005690433,0.0005084884,0.000327424,0.0003783279,0.0009499248,0.00003447628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817555,0.0121586,0.0007898927,0.0005975288,0.0008503076,0.001257345,0.0006756121,0.00007642703,0.001838808],"genre_scores_gemma":[0.9895954,0.00396884,0.001224733,0.0009354108,0.0004408683,0.001239826,0.0006106239,0.00002184368,0.001962509],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003432487,"threshold_uncertainty_score":0.01148278,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09033592788829715,"score_gpt":0.3633928836903327,"score_spread":0.2730569558020355,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}